Synthomer 배당 및 자사주 매입
배당 기준 점검 0/6
Synthomer 현재 배당금을 지급하지 않습니다.
핵심 정보
0%
배당 수익률
0.06%
자사주 매입 수익률
| 총 주주 수익률 | 0.06% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | 0% |
최근 배당 및 자사주 매입 업데이트
Recent updates
SYNT: Higher Profitability Assumptions And Execution On Plans Will Support Future Upside
Analysts have trimmed their fair value estimate for Synthomer from £1.47 to £1.28, even as recent price target increases on the stock point to updated views on revenue growth, profitability and future P/E assumptions. Analyst Commentary Recent research on Synthomer gives investors a mixed message.Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results
Shareholders will be ecstatic, with their stake up 39% over the past week following Synthomer plc 's ( LON:SYNT...SYNT: Higher Fair Value And Execution Risks Will Shape Future Earnings
Analysts have raised their price target on Synthomer to £0.92 from £0.62, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key factors supporting the new level. Analyst Commentary Recent research updates on Synthomer suggest that, while targets have been adjusted, many analysts remain cautious about the stock.SYNT: Recent Price Objective Revisions Will Shape A More Constructive Outlook
The Analyst Price Target on Synthomer has been adjusted from £3.48 to £2.00 per share, reflecting analysts' updated assumptions on fair value, discount rate, and earnings profile in light of recent price target increases from £0.62 to £0.92 and an additional £0.40 uplift cited in Street research. Analyst Commentary Recent Street research on Synthomer points to a more constructive tone, with bullish analysts revisiting their fair value assumptions and revising price targets.SYNT: Cost Actions And Execution On Plans Will Support Future Upside
Analysts have lifted their fair value estimate for Synthomer from £1.27 to £1.47, reflecting higher price targets from the Street and updated assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street commentary on Synthomer points to a more constructive stance on the stock, with price targets moving higher and ratings generally sitting in the neutral range.SYNT: Leadership Change And Higher Risk Profile Will Pressure Future Earnings
Analysts have lifted their price target on Synthomer by £0.40, citing updated assumptions around discount rates, revenue growth and future P/E that they view as better aligned with the company’s current risk and earnings profile. What’s in the News for Synthomer Synthomer announced that Chief Financial Officer Lily Liu plans to step down to become Executive Vice President and Chief Financial Officer at Umicore SA.SYNT: Leadership Transition Will Intensify Concerns Over Future Margin Stability
Analysts have nudged Synthomer's fair value higher, lifting the implied price target from £0.59 to £0.62. This reflects refreshed assumptions on revenue growth, discount rate and future P/E.SYNT: Bio-Based Shift Will Face Margin And Leadership Risks Ahead
Analysts have kept their Synthomer fair value target steady at £0.59. This reflects a view that a shift from a previous revenue contraction of 32.37% to expected growth of 2.61%, together with a slightly lower projected profit margin of 9.99%, leaves the overall valuation framework broadly unchanged.SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
There's been a major selloff in Synthomer plc ( LON:SYNT ) shares in the week since it released its half-year report...Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Synthomer plc's ( LON:SYNT ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
You may think that with a price-to-sales (or "P/S") ratio of 0.2x Synthomer plc ( LON:SYNT ) is a stock worth checking...Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£2.63 With UK£2.46 share...Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
Synthomer plc ( LON:SYNT ) shares have continued their recent momentum with a 27% gain in the last month alone. Still...Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£1.84 Current share price...Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Synthomer plc ( LON:SYNT ) shareholders would be excited to see that the share price has had a great month, posting a...Should You Think About Buying Synthomer plc (LON:SYNT) Now?
While Synthomer plc ( LON:SYNT ) might not have the largest market cap around , it saw a double-digit share price rise...지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 SYNT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: SYNT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| Synthomer 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (SYNT) | 0% |
| 시장 하위 25% (GB) | 2.1% |
| 시장 상위 25% (GB) | 5.3% |
| 업계 평균 (Chemicals) | 3.7% |
| 분석가 예측 (SYNT) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SYNT 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SYNT 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: SYNT UK 시장에서 주목할만한 배당금을 지급하지 않습니다.
주주 현금 배당
현금 흐름 범위: SYNT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/20 20:15 |
| 종가 | 2026/08/20 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Synthomer plc는 18명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Katie Richards | Barclays |
| James Stewart | Barclays |
| Robert Bate | Barclays |